Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not
Source: SeekingAlpha
2026-02-20 07:30:47 ET
In January, I rated Corcept Therapeutics ( CORT ) a Hold , citing severe binary risk of its looming patent appeal against Teva Teva Pharmaceutical Industries ( TEVA ). On February 19th, the US Court of Appeals for the Federal Circuit affirmed the lower court's ruling, siding with Teva. As a consequence, a generic version of Corcept's drug Korlym will soon be on the market, calling into question all of Corcept's sales....
Read the full article on Seeking Alpha
For further details see:
Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not
Corcept Therapeutics Incorporated
NASDAQ: CORT
CORT Trading
-2.18% G/L:
$31.86 Last:
301,911 Volume:
$32.77 Open:
CORT Latest News
March 10, 2026 06:00:00 pm
REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026
March 03, 2026 10:03:29 am
Investors of Corcept Therapeutics, Inc. (CORT) Seeking Recovery - Contact Kaplan Fox Before Deadline on April 21, 2026
CORT Stock Data
$4,351,636,537
83,309,068
0.22%
163
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
